Prognostic Value of PARS Classification for Locally Recurrent Rectal Cancer

Launched by SIXTH AFFILIATED HOSPITAL, SUN YAT-SEN UNIVERSITY · Jan 31, 2025

Keywords

ClinConnect Summary

With the introduction of total mesorectal excision (TME) and neoadjuvant chemoradiotherapy, the local recurrence rate of rectal cancer after surgery has markedly decreased; however, 5-18% of patients still experience recurrence in the pelvic field, significantly affecting their quality of life and contributing to high mortality rates. Several clinical and histologic features have been associated with the development of locally recurrent rectal cancer (LRRC), including higher primary T/N stage, positive margins, distal tumors, and histopathologic risk features such as tumor deposits (TD), ly...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • (1) the primary tumor was located in the sigmoid colon or rectum, following prior radical tumor resection;
• • (2) local recurrence was confirmed through CT, MRI, and serum cancer biomarker test, or endoscopic biopsy;
• • (3) the recurrent site was confined to the pelvis;
• • (4) the recurrent tumor underwent R0 or R1 surgical resection;
• • (5) the absence of uncontrollable distant metastases at the time of salvage radical surgery.
• Exclusion Criteria:
• • (1) patients with unresectable tumors identified before salvage radical surgery, leading to palliative therapy;
• • (2) a recurrence interval of less than three months;
• • (3) incomplete baseline characteristics, including pathologic data from the initial treatment;
• • (4) loss to follow-up.